Market Closed -
Nasdaq
02:19:54 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
1.39
USD
|
+0.72%
|
|
-0.71%
|
-7.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
295.9
|
236.3
|
131.4
|
100.5
|
73.57
|
68.17
|
-
|
-
|
Enterprise Value (EV)
1 |
295.9
|
176.3
|
131.4
|
100.5
|
73.57
|
68.17
|
68.17
|
68.17
|
P/E ratio
|
-22.5
x
|
-17
x
|
-12.8
x
|
-7.07
x
|
-8.82
x
|
-6.04
x
|
-5.79
x
|
-5.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
32.6
x
|
-
|
73.6
x
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
32.6
x
|
-
|
73.6
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-16,692,748
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-32,390,079
x
|
-21,754,779
x
|
-13,967,179
x
|
-7,784,172
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.95
x
|
3.32
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
43,906
|
44,928
|
49,043
|
49,046
|
49,046
|
49,046
|
-
|
-
|
Reference price
2 |
6.740
|
5.260
|
2.680
|
2.050
|
1.500
|
1.390
|
1.390
|
1.390
|
Announcement Date
|
2/13/20
|
2/19/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
4.038
|
-
|
1
|
-
|
-
|
-
|
EBITDA
|
-
|
-14.16
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.03
|
-14.18
|
-10.22
|
-14.63
|
-9.9
|
-11.8
|
-11.7
|
-12.1
|
Operating Margin
|
-
|
-
|
-253.02%
|
-
|
-990.03%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.93
|
-13.86
|
-10.13
|
-14.07
|
-8.568
|
-11.4
|
-11.7
|
-12.1
|
Net income
1 |
-12.94
|
-13.85
|
-10.13
|
-14.07
|
-8.572
|
-11.4
|
-11.7
|
-12.1
|
Net margin
|
-
|
-
|
-251%
|
-
|
-857.15%
|
-
|
-
|
-
|
EPS
2 |
-0.3000
|
-0.3100
|
-0.2100
|
-0.2900
|
-0.1700
|
-0.2300
|
-0.2400
|
-0.2400
|
Free Cash Flow
|
-9.136
|
-10.86
|
-9.41
|
-12.92
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-233.07%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/19/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.103
|
-3.41
|
-4.09
|
-3.897
|
-3.231
|
-2.963
|
-3.3
|
-1.147
|
-2.49
|
-3.136
|
-2.8
|
-2.9
|
-3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-114.69%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.081
|
-3.386
|
-4.029
|
-3.652
|
-2.999
|
-2.918
|
-2.872
|
-0.7231
|
-2.056
|
-2.755
|
-2.8
|
-2.9
|
-3
|
Net income
1 |
-2.083
|
-3.386
|
-4.029
|
-3.652
|
-3.001
|
-2.918
|
-2.872
|
-0.7231
|
-2.059
|
-2.755
|
-2.8
|
-2.9
|
-3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-72.31%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0400
|
-0.0700
|
-0.0800
|
-0.0700
|
-0.0600
|
-0.0600
|
-0.0600
|
-0.0100
|
-0.0400
|
-0.0600
|
-0.0600
|
-0.0600
|
-0.0600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/16/22
|
5/12/22
|
8/11/22
|
11/10/22
|
2/16/23
|
5/11/23
|
8/9/23
|
11/9/23
|
2/15/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
60
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-9.14
|
-10.9
|
-9.41
|
-12.9
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-17.5%
|
-19%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-16.5%
|
-17.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
78.22
|
77.31
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
1.710
|
1.580
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.01
|
0.04
|
0.03
|
0.01
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
0.71%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/19/21
|
2/16/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
1.39
USD Average target price
16
USD Spread / Average Target +1,051.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.33% | 68.17M | | +20.95% | 127B | | +23.00% | 117B | | +25.82% | 27.77B | | -19.75% | 20.44B | | -15.03% | 16.62B | | -16.56% | 15.92B | | +11.19% | 14.74B | | -46.65% | 14.94B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|